Cardiovascular Protection in PAD and Post-PCI: Planning Beyond the Revascularization

Faculty and Program

	Eric Secemsky, MD, MSc, FSCAI Atherothrombotic Risk Reduction in CAD, PAD, or Both		Sandeep Nathan, MD, MSc, FSCAI Moderator Case 1: Polyvascular Disease Patient: S/P Multivessel CAD PCI and New Diagnosis of PAD
	Marc Bonaca, MD, MPH PAD and PVI Pharmacotherapy		Dmitriy N. Feldman, MD, FSCAI Case 2: PAD Patient Undergoing Lower Extremity PVI for CLTI

Learning Objectives

Upon completion of this activity, participants will be able to:

Discuss the residual risk for atherothrombotic events, stroke and vascular death in patients with CAD, PAD or both
Interpret the contemporary data on combined therapy with aspirin and DOAC in patients with polyvascular disease
Optimize the balance of bleeding risk and antithrombotic benefit in patients with PAD who underwent peripheral revascularization
Assess the interplay of patient-specific factors (e.g. type and timing of revascularization, comorbidities, concomitant medications) and antithrombotic therapy

Acknowledgement of Commercial Support

This activity is sponsored by SCAI and supported by Janssen.

Continuing Education Information

This activity is not certified for accredited continuing education.

Summary


Cost:	FREE

Credit Offered:

1 Participation Credit